Cynata Therapeutics
Stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology.
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
Visit website: https://www.cynata.com/
Details last updated 15-Jan-2020
Cynata Therapeutics News
Fujifilm to test stem cells in leukemia treatment
Nikkei - 23-Sep-2018
A company is looking to start trials for induced stem cells to fight graft vs host disease
Read more...